<!--
Homepage version latest-updates

Instruction:

1. Always use three hashtags (###) to start a section title.

2. Please include an anchor link to the detailed latest updates page in each section title.
   You can click the üîó symbol on detailed latest updates page to find out the corresponding anchor link.
   Please follow the existing sections for the correct format.

3. One paragraph description for each section. The paragraph should contain less than ~200 chars.

4. Dated updates should be listed in descending order.

5. For links from covdb.stanford.edu, please remove the leading "https://covdb.stanford.edu".
   For example, "https://covdb.stanford.edu/page/updates/" should be shorten to "/page/updates/".

6. Try not to include plain links such as [https://stanford.cloud-cme.com/default.aspx?P=0&EID=38044](https://stanford.cloud-cme.com/default.aspx?P=0&EID=38044).
   Please include readable content in the bracket, e.g. [video](https://stanford.cloud-cme.com/default.aspx?P=0&EID=38044).

7. Please do not delete this instruction.

-->
### Database Entries (Jun 22)
Horby PW, Mafham M, et int., and Landray MJ. [‚ÄúCasirivimab and imdevimab in patients admitted to hospital with COVID-19 (RECOVERY): a randomised, controlled, open-label, platform trial.‚Äù](/search/?article=Horby21) _medRxiv_, 2021. [doi.org/10.1101/2021.06.15.21258542](https://doi.org/10.1101/2021.06.15.21258542).
### Database Entries (Jun 22)
Liu C, Ginn HM, et int., and Screaton GR. [‚ÄúReduced neutralization of SARS-CoV-2 B.1.617 by vaccine and convalescent serum.‚Äù](/search-drdb/?article=Liu21f) _Cell_, 2021. [doi.org/10.1016/j.cell.2021.06.020](https://doi.org/10.1016/j.cell.2021.06.020).
### Database Entries (Jun 22)
O‚ÄôBrien MP, Forleo-Neto E, et int., and Weinreich DM. [‚ÄúSubcutaneous REGEN-COV Antibody Combination in Early SARS-CoV-2 Infection.‚Äù](/search/?article=Obrien21) _medRxiv_, 2021. [doi.org/10.1101/2021.06.14.21258569](https://doi.org/10.1101/2021.06.14.21258569).
### Database Entries (Jun 22)
Walser M, Rothenberger S, et int., and Amstutz P. [‚ÄúHighly potent anti-SARS-CoV-2 multi-DARPin therapeutic candidates.‚Äù](/search/?article=Walser20) _bioRxiv_, 2020. [doi.org/10.1101/2020.08.25.256339](https://doi.org/10.1101/2020.08.25.256339).
### Database Entries (Jun 22)
Zou J, Xie X, et int., and Shi P. [‚ÄúThe effect of SARS-CoV-2 D614G mutation on BNT162b2 vaccine-elicited neutralization.‚Äù](/search-drdb/?article=Zou21) _npj Vaccines_, 2021. [doi.org/10.1038/s41541-021-00313-8](https://doi.org/10.1038/s41541-021-00313-8). \[[PubMed33767200](https://www.ncbi.nlm.nih.gov/pubmed/33767200/)\] \[[PMC7994717](https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7994717/)\]
### Database Entries (Jun 15)
Hirotsu Y, and Omata M. [‚ÄúDetection of R.1 lineage severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) with spike protein W152L/E484K/G769V mutations in Japan.‚Äù](/search-drdb/?article=Hirotsu21) _PLOS Pathogens_, 2021. [doi.org/10.1371/journal.ppat.1009619](https://doi.org/10.1371/journal.ppat.1009619). \[[PubMed34097716](https://www.ncbi.nlm.nih.gov/pubmed/34097716/)\]
### Database Entries (Jun 12)
Varona JF, Landete P, et int., and Garc√≠a-Sastre A. [‚ÄúPlitidepsin has a positive therapeutic index in adult patients with COVID-19 requiring hospitalization.‚Äù](/search/?article=Varona21) _medRxiv_, 2021. [doi.org/10.1101/2021.05.25.21257505](https://doi.org/10.1101/2021.05.25.21257505). \[[PubMed34075384](https://www.ncbi.nlm.nih.gov/pubmed/34075384/)\] \[[PMC8168388](https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8168388/)\]
### Database Entries (Jun 12)
Yu J, Lu X, et int., and Li L. [‚ÄúInterferon‚ÄêŒ±‚Äê2b aerosol inhalation is associated with improved clinical outcomes in patients with coronavirus disease‚Äê2019.‚Äù](/search/?article=Yu21) _British Journal of Clinical Pharmacology_, 2021. [doi.org/10.1111/bcp.14898](https://doi.org/10.1111/bcp.14898). \[[PubMed33982806](https://www.ncbi.nlm.nih.gov/pubmed/33982806/)\]
### Database Entries (Jun 12)
Planas D, Veyer D, et int., and Schwartz O. [‚ÄúReduced sensitivity of infectious SARS-CoV-2 variant B.1.617.2 to monoclonal antibodies and sera from convalescent and vaccinated individuals.‚Äù](/search-drdb/?article=Planas21b) _bioRxiv_, 2021. [doi.org/10.1101/2021.05.26.445838](https://doi.org/10.1101/2021.05.26.445838).
### [Clinical Trials (Jun 07)](/page/updates/#clinical.trials)
[5 clinical trials from ClinicalTrials.gov and WHO ICTRP were added to the registry of Ongoing and Planned Clinical Trials of Antiviral Compounds.](/clinical-trials/?fromDate=2021-06-07)
### Database Entries (May 28)
Gonzalez C, Saade C, et int., and Pozzetto B. [‚ÄúLive virus neutralisation testing in convalescent patients and subjects vaccinated against 19A, 20B, 20I/501Y.V1 and 20H/501Y.V2 isolates of SARS-CoV-2.‚Äù](/search-drdb/?article=Gonzalez21) _medRxiv_, 2021. [doi.org/10.1101/2021.05.11.21256578](https://doi.org/10.1101/2021.05.11.21256578).
### Database Entries (May 28)
Liu Y, Liu J, et int., and Shi P. [‚ÄúBNT162b2-Elicited Neutralization against New SARS-CoV-2 Spike Variants.‚Äù](/search-drdb/?article=Liu21d) _New England Journal of Medicine_, 2021. [doi.org/10.1056/nejmc2106083](https://doi.org/10.1056/nejmc2106083). \[[PubMed33979486](https://www.ncbi.nlm.nih.gov/pubmed/33979486/)\] \[[PMC8133696](https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8133696/)\]
### Database Entries (May 28)
Makdasi E, Zvi A, et int., and Rosenfeld R. [‚ÄúThe neutralization potency of anti-SARS-CoV-2 therapeutic human monoclonal antibodies is retained against novel viral variants.‚Äù](/search-drdb/?article=Makdasi21) _bioRxiv_, 2021. [doi.org/10.1101/2021.04.01.438035](https://doi.org/10.1101/2021.04.01.438035).
### Database Entries (May 28)
Muecksch F, Weisblum Y, et int., and Bieniasz PD. [‚ÄúDevelopment of potency, breadth and resilience to viral escape mutations in SARS-CoV-2 neutralizing antibodies.‚Äù](/search-drdb/?article=Muecksch21) _bioRxiv_, 2021. [doi.org/10.1101/2021.03.07.434227](https://doi.org/10.1101/2021.03.07.434227). \[[PubMed33758864](https://www.ncbi.nlm.nih.gov/pubmed/33758864/)\] \[[PMC7987023](https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7987023/)\]
### Database Entries (May 28)
Pegu A, O‚ÄôConnell S, et int., and Doria-Rose NA. [‚ÄúDurability of mRNA-1273-induced antibodies against SARS-CoV-2 variants.‚Äù](/search-drdb/?article=Pegu21) _bioRxiv_, 2021. [doi.org/10.1101/2021.05.13.444010](https://doi.org/10.1101/2021.05.13.444010). \[[PubMed34031659](https://www.ncbi.nlm.nih.gov/pubmed/34031659/)\] \[[PMC8142657](https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8142657/)\]
### Database Entries (May 28)
Shi P, Liu J, et int., and Dormitzer P. [‚ÄúNeutralization of SARS-CoV-2 variants B.1.617.1 and B.1.525 by BNT162b2-elicited sera.‚Äù](/search-drdb/?article=Shi21) _Research Square_, 2021. [doi.org/10.21203/rs.3.rs-540721/v1](https://doi.org/10.21203/rs.3.rs-540721/v1).
### Database Entries (May 28)
Tada T, Zhou H, et int., and Landau NR. [‚ÄúThe Spike Proteins of SARS-CoV-2 B.1.617 and B.1.618 Variants Identified in India Provide Partial Resistance to Vaccine-elicited and Therapeutic Monoclonal Antibodies.‚Äù](/search-drdb/?article=Tada21c) _bioRxiv_, 2021. [doi.org/10.1101/2021.05.14.444076](https://doi.org/10.1101/2021.05.14.444076).
### Database Entries (May 28)
Yi C, Sun X, et int., and Sun B. [‚ÄúComprehensive Mapping of Binding Hot Spots of SARS-CoV-2 RBD-specific Neutralizing Antibodies for Tracking Immune Escape Variants.‚Äù](/search-drdb/?article=Yi21) _Research Square_, 2021. [doi.org/10.21203/rs.3.rs-497595/v1](https://doi.org/10.21203/rs.3.rs-497595/v1).
### Database Entries (May 28)
Zhang L, Cui Z, et int., and Wang Y. [‚ÄúComparison of 10 emerging SARS-CoV-2 Variants: infectivity, animal tropism, and antibody neutralization.‚Äù](/search-drdb/?article=Zhang21c) _Research Square_, 2021. [doi.org/10.21203/rs.3.rs-492659/v1](https://doi.org/10.21203/rs.3.rs-492659/v1).
### [Clinical Trials (May 28)](/page/updates/#clinical.trials)
[12 clinical trials from ClinicalTrials.gov and WHO ICTRP were added to the registry of Ongoing and Planned Clinical Trials of Antiviral Compounds.](/clinical-trials/?fromDate=2021-05-28)

### Database Entries (May 13)
Betton M, Livrozet M, et int., and Hulot J. [‚ÄúSera neutralizing activities against SARS-CoV-2 and multiple variants six month after hospitalization for COVID-19.‚Äù](/search-drdb/?article=Betton21) _Clinical Infectious Diseases_, 2021. [doi.org/10.1093/cid/ciab308](https://doi.org/10.1093/cid/ciab308). \[[PubMed33851216](https://www.ncbi.nlm.nih.gov/pubmed/33851216/)\] \[[PMC8083257](https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8083257/)\]
### Database Entries (May 13)
Dudas G, Hong SL, et int., and Baele G. [‚ÄúTravel-driven emergence and spread of SARS-CoV-2 lineage B.1.620 with multiple VOC-like mutations and deletions in Europe.‚Äù](/search-drdb/?article=Dudas21) _medRxiv_, 2021. [doi.org/10.1101/2021.05.04.21256637](https://doi.org/10.1101/2021.05.04.21256637).
### Database Entries (May 13)
Edara VV, Norwood C, et int., and Suthar MS. [‚ÄúInfection- and vaccine-induced antibody binding and neutralization of the B.1.351 SARS-CoV-2 variant.‚Äù](/search-drdb/?article=Edara21b) _Cell Host & Microbe_, 2021. [doi.org/10.1016/j.chom.2021.03.009](https://doi.org/10.1016/j.chom.2021.03.009). \[[PubMed33798491](https://www.ncbi.nlm.nih.gov/pubmed/33798491/)\] \[[PMC7980225](https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7980225/)\]
### Database Entries (May 13)
Edara V, Lai L, et int., and Suthar MS. [‚ÄúInfection and vaccine-induced neutralizing antibody responses to the SARS-CoV-2 B.1.617.1 variant.‚Äù](/search-drdb/?article=Edara21c) _bioRxiv_, 2021. [doi.org/10.1101/2021.05.09.443299](https://doi.org/10.1101/2021.05.09.443299).
### Database Entries (May 13)
Ferreira I, Datir R, et int., and Gupta RK. [‚ÄúSARS-CoV-2 B.1.617 emergence and sensitivity to vaccine-elicited antibodies.‚Äù](/search-drdb/?article=Ferreira21) _bioRxiv_, 2021. [doi.org/10.1101/2021.05.08.443253](https://doi.org/10.1101/2021.05.08.443253).
### Database Entries (May 13)
Goel RR, Apostolidis SA, et int., and Wherry EJ. [‚ÄúDistinct antibody and memory B cell responses in SARS-CoV-2 na√Øve and recovered individuals following mRNA vaccination.‚Äù](/search-drdb/?article=Goel21) _Science Immunology_, 2021. [doi.org/10.1126/sciimmunol.abi6950](https://doi.org/10.1126/sciimmunol.abi6950). \[[PubMed33858945](https://www.ncbi.nlm.nih.gov/pubmed/33858945/)\]
### Database Entries (May 13)
Hoffmann M, Hofmann-Winkler H, et int., and P√∂hlmann S. [‚ÄúSARS-CoV-2 variant B.1.617 is resistant to Bamlanivimab and evades antibodies induced by infection and vaccination.‚Äù](/search-drdb/?article=Hoffmann21c) _bioRxiv_, 2021. [doi.org/10.1101/2021.05.04.442663](https://doi.org/10.1101/2021.05.04.442663).
### Database Entries (May 13)
Jalkanen P, Kolehmainen P, et int., and Julkunen I. [‚ÄúCOVID-19 mRNA vaccine induced antibody responses and neutralizing antibodies against three SARS-CoV-2 variants.‚Äù](/search-drdb/?article=Jalkanen21) _Research Square_, 2021. [doi.org/10.21203/rs.3.rs-343388/v1](https://doi.org/10.21203/rs.3.rs-343388/v1).
### Database Entries (May 13)
Laiton-Donato K, Franco-Mu√±oz C, et int., and Mercado-Reyes M. [‚ÄúCharacterization of the emerging B.1.621 variant of interest of SARS-CoV-2.‚Äù](/search-drdb/?article=Laiton-Donato21) _medRxiv_, 2021. [doi.org/10.1101/2021.05.08.21256619](https://doi.org/10.1101/2021.05.08.21256619).
### Database Entries (May 13)
Li R, Ma X, et int., and Zhang H. [‚ÄúDifferential efficiencies to neutralize the novel mutants B.1.1.7 and 501Y.V2 by collected sera from convalescent COVID-19 patients and RBD nanoparticle-vaccinated rhesus macaques.‚Äù](/search-drdb/?article=Li21d) _Cellular & Molecular Immunology_, 2021. [doi.org/10.1038/s41423-021-00641-8](https://doi.org/10.1038/s41423-021-00641-8). \[[PubMed33580167](https://www.ncbi.nlm.nih.gov/pubmed/33580167/)\] \[[PMC7880638](https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7880638/)\]
### Database Entries (May 13)
Lien C, Kuo T, et int., and Chen C. [‚ÄúEvaluating the neutralizing ability of a CpG-adjuvanted S-2P subunit vaccine against SARS-CoV-2 Variants of Concern.‚Äù](/search-drdb/?article=Lien21) _medRxiv_, 2021. [doi.org/10.1101/2021.03.19.21254000](https://doi.org/10.1101/2021.03.19.21254000).
### Database Entries (May 13)
Monin-Aldama L, Laing AG, et int., and Irshad S. [‚ÄúInterim results of the safety and immune-efficacy of 1 versus 2 doses of COVID-19 vaccine BNT162b2 for cancer patients in the context of the UK vaccine priority guidelines.‚Äù](/search-drdb/?article=Monin-Aldama21) _medRxiv_, 2021. [doi.org/10.1101/2021.03.17.21253131](https://doi.org/10.1101/2021.03.17.21253131).
### Database Entries (May 13)
Sapkal GN, Yadav PD, et int., and Bhargava B. [‚ÄúInactivated COVID-19 vaccine BBV152/COVAXIN effectively neutralizes recently emerged B.1.1.7 variant of SARS-CoV-2.‚Äù](/search-drdb/?article=Sapkal21b) _Journal of Travel Medicine_, 2021. [doi.org/10.1093/jtm/taab051](https://doi.org/10.1093/jtm/taab051). \[[PubMed33772577](https://www.ncbi.nlm.nih.gov/pubmed/33772577/)\] \[[PMC8083765](https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8083765/)\]
### Database Entries (May 13)
Stankov MV, Cossmann A, et int., and Behrens GM. [‚ÄúHumoral and cellular immune responses against SARS-CoV-2 variants and human coronaviruses after single BNT162b2 vaccination.‚Äù](/search-drdb/?article=Stankov21) _medRxiv_, 2021. [doi.org/10.1101/2021.04.16.21255412](https://doi.org/10.1101/2021.04.16.21255412).
### Database Entries (May 13)
Virtanen J, Uusitalo R, et int., and Vapalahti O. [‚ÄúReduced neutralization of B.1.351 variant SARS-CoV-2 by convalescent sera of COVID-19 patients.‚Äù](/search-drdb/?article=Virtanen21) _Research Square_, 2021. [doi.org/10.21203/rs.3.rs-279522/v1](https://doi.org/10.21203/rs.3.rs-279522/v1).
### Database Entries (May 13)
Weigang S, Fuchs J, et int., and Kochs G. [‚ÄúWithin-host evolution of SARS-CoV-2 in an immunosuppressed COVID-19 patient: a source of immune escape variants.‚Äù](/search-drdb/?article=Weigang21) _medRxiv_, 2021. [doi.org/10.1101/2021.04.30.21256244](https://doi.org/10.1101/2021.04.30.21256244).

### Database Entries (May 05)
Ryu D, Song R, et int., and Lee S. [‚ÄúTherapeutic effect of CT-P59 against SARS-CoV-2 South African variant.‚Äù](/search/?article=Lee21) _bioRxiv_, 2021. [doi.org/10.1101/2021.04.27.441707](https://doi.org/10.1101/2021.04.27.441707).
### Database Entries (May 05)
Lenze EJ, Mattar C, et int., and Reiersen AM. [‚ÄúFluvoxamine vs Placebo and Clinical Deterioration in Outpatients With Symptomatic COVID-19.‚Äù](/search/?article=Lenze20) _JAMA_, 2020. [doi.org/10.1001/jama.2020.22760](https://doi.org/10.1001/jama.2020.22760). \[[PubMed33180097](https://www.ncbi.nlm.nih.gov/pubmed/33180097/)\] \[[PMC7662481](https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7662481/)\]

### [Clinical Trials (Apr 29)](/page/updates/#clinical.trials)
[6 clinical trials from ClinicalTrials.gov and WHO ICTRP were added to the registry of Ongoing and Planned Clinical Trials of Antiviral Compounds.](/clinical-trials/?fromDate=2021-04-29)

### Database Entries (Apr 26)
Gaborit B, Dailly E, et int., and Raffi F. [‚ÄúPharmacokinetics and safety of XAV-19, a swine glyco-humanized polyclonal anti-SARS-CoV-2 antibody, for COVID-19-related moderate pneumonia: a randomized, double-blind, placebo-controlled, phase IIa study.‚Äù](/search/?article=Gaborit21) _medRxiv_, 2021. [doi.org/10.1101/2021.04.15.21255549](https://doi.org/10.1101/2021.04.15.21255549).
### Database Entries (Apr 26)
Gunst JD, Staerke NB, et int., and S√∏gaard OS. [‚ÄúEfficacy of the TMPRSS2 inhibitor camostat mesilate in patients hospitalized with Covid-19-a double-blind randomized controlled trial.‚Äù](/search/?article=Gunst21) _EClinicalMedicine_, 2021. [doi.org/10.1016/j.eclinm.2021.100849](https://doi.org/10.1016/j.eclinm.2021.100849).
### Database Entries (Apr 26)
Lopardo G, Belloso WH, et int., and Goldbaum F. [‚ÄúRBD-specific polyclonal F(ab¬¥)2 fragments of equine antibodies in patients with moderate to severe COVID-19 disease: A randomized, multicenter, double-blind, placebo-controlled, adaptive phase 2/3 clinical trial.‚Äù](/search/?article=Lopardo21) _EClinicalMedicine_, 2021. [doi.org/10.1016/j.eclinm.2021.100843](https://doi.org/10.1016/j.eclinm.2021.100843). \[[PubMed33870149](https://www.ncbi.nlm.nih.gov/pubmed/33870149/)\] \[[PMC8037439](https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8037439/)\]
### Database Entries (Apr 26)
Qiao J, Li Y, et int., and Yang S. [‚ÄúSARS-CoV-2 Mpro inhibitors with antiviral activity in a transgenic mouse model.‚Äù](/search/?article=Qiao21) _Science_, 2021. [doi.org/10.1126/science.abf1611](https://doi.org/10.1126/science.abf1611). \[[PubMed33602867](https://www.ncbi.nlm.nih.gov/pubmed/33602867/)\]
### Database Entries (Apr 26)
Rossignol J, Bardin MC, et int., and Brechot C. [‚ÄúEarly treatment with nitazoxanide prevents worsening of mild and moderate COVID-19 and subsequent hospitalization.‚Äù](/search/?article=Rossignol21) _medRxiv_, 2021. [doi.org/10.1101/2021.04.19.21255441](https://doi.org/10.1101/2021.04.19.21255441).
### Database Entries (Apr 26)
Silva M, Espejo A, et int., and Enriquez D. [‚ÄúEfficacy of Nitazoxanide in reducing the viral load in COVID-19 patients. Randomized, placebo-controlled, single-blinded, parallel group, pilot study.‚Äù](/search/?article=Silva21) _medRxiv_, 2021. [doi.org/10.1101/2021.03.03.21252509](https://doi.org/10.1101/2021.03.03.21252509).
### [Clinical Trials (Apr 22)](/page/updates/#clinical.trials)
[2 clinical trials from ClinicalTrials.gov and WHO ICTRP were added to the registry of Ongoing and Planned Clinical Trials of Antiviral Compounds.](/clinical-trials/?fromDate=2021-04-22)

### Database Entries (Apr 19)
Greaney AJ, Loes AN, et int., and Bloom JD. ‚ÄúThe SARS-CoV-2 mRNA-1273 vaccine elicits more RBD-focused neutralization, but with broader antibody binding within the RBD.‚Äù _bioRxiv_, 2021. [doi.org/10.1101/2021.04.14.439844](https://doi.org/10.1101/2021.04.14.439844).
### Database Entries (Apr 19)
Ikegame S, Siddiquey MNA, et int., and Lee B. ‚ÄúQualitatively distinct modes of Sputnik V vaccine-neutralization escape by SARS-CoV-2 Spike variants.‚Äù _medRxiv_, 2021. [doi.org/10.1101/2021.03.31.21254660](https://doi.org/10.1101/2021.03.31.21254660). \[[PubMed33821288](https://www.ncbi.nlm.nih.gov/pubmed/33821288/)\] \[[PMC8020991](https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8020991/)\]
### Database Entries (Apr 19)
Vandyck K, Abdelnabi R, et int., and Neyts J. [‚ÄúALG-097111, a potent and selective SARS-CoV-2 3-chymotrypsin-like cysteine protease inhibitor exhibits in¬†vivo efficacy in a Syrian Hamster model.‚Äù](/search/?article=Vandyck21) _Biochemical and Biophysical Research Communications_, 2021. [doi.org/10.1016/j.bbrc.2021.03.096](https://doi.org/10.1016/j.bbrc.2021.03.096). \[[PubMed33813272](https://www.ncbi.nlm.nih.gov/pubmed/33813272/)\] \[[PMC7997389](https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7997389/)\]
### [Clinical Trials (Apr 15)](/page/updates/#clinical.trials)
[7 clinical trials from ClinicalTrials.gov and WHO ICTRP were added to the registry of Ongoing and Planned Clinical Trials of Antiviral Compounds.](/clinical-trials/?fromDate=2021-04-15)
### Database Entries (Apr 11)
Maisonnasse P, Aldon Y, et int., and Grand RL. [‚ÄúCOVA1-18 neutralizing antibody protects against SARS-CoV-2 in three preclinical models.‚Äù](/search/?article=Maisonnasse21) _Research Square_, 2021. [doi.org/10.21203/rs.3.rs-235272/v1](https://doi.org/10.21203/rs.3.rs-235272/v1). \[[PubMed33619476](https://www.ncbi.nlm.nih.gov/pubmed/33619476/)\] \[[PMC7899470](https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7899470/)\]
### Database Entries (Apr 11)
Suryadevara N, Shrihari S, et int., and Crowe JE. [‚ÄúNeutralizing and protective human monoclonal antibodies recognizing the N-terminal domain of the SARS-CoV-2 spike protein.‚Äù](/search/?article=Suryadevara21) _Cell_, 2021. [doi.org/10.1016/j.cell.2021.03.029](https://doi.org/10.1016/j.cell.2021.03.029). \[[PubMed33773105](https://www.ncbi.nlm.nih.gov/pubmed/33773105/)\] \[[PMC7962591](https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7962591/)\]
